[1] Nef H M, Mollmann H, Hamm C, et al. Pulmonary hypertension: updated classification and management of pulmonary hypertension[J]. Heart, 2010, 96(7): 552-559. [2] Fernańdez R A, Sundivakkam P, Smith K A, et al. Pathogenic role of store-operated and receptor-operated Ca2+channels in pulmonary arterial hypertension[J]. J Signal Transduct, 2012, 2012:951497. [3] Meloche J, Renard S, Provencher S, et al. Anti-inflammatory and immunosuppressive agents in PAH[J]. Handb Exp Pharmacol, 2013, 218:437-476. [4] Yoon J, Ryoo S. Arginase inhibition reduces interleukin-1β-stimulated vascular smooth muscle cell proliferation by increasing nitric oxide synthase-dependent nitric oxide production[J]. Biochem Biophys Res Commun, 2013, 435(3):428-433. [5] Lamkanfi M, Kanneganti T D. Nlrp3: an immune sensor of cellular stress and infection[J]. Int J Biochem Cell Biol, 2010, 42(6): 792-795. [6] Schroder K, Tschopp J. The Inflammasomes[J]. Cell, 2010, 140(6):821-832. [7] Lamkanfi M, Mueller J L, Vitari A C, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome[J]. J Cell Biol, 2009, 187(1):61-70. [8] Thomas H C, Lamé M W, Dunston S K, et al. Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells[J]. Toxicol Appl Pharmacol, 1998, 151(2):236-244. [9] 刘杰,杜雨轩,王望,等. 雷帕霉素对野百合碱诱导的大鼠肺动脉高压及肺血管重构的影响[J]. 首都医科大学学报,2013,34(4) :554-558. [10] Montani D, Günther S, Dorfmüller P, et al. Pulmonary arterial hypertension[J]. Orphanet J Rare Dis, 2013, 8:97. [11] Montani D, Chaumais M C, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension[J]. Pharmacol Ther, 2014, 141(2):172-191. [12] Tuder R M, Groves B, Badesch D B, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension[J]. Am J Pathol, 1994, 144(2):275-285. [13] Frid M G, Brunetti J A, Burke D L, et al. Hypoxia induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage[J]. Am J Pathol, 2006, 168(2): 659-669. [14] Soon E, Holmes A M, Treacy C M, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension[J]. Circulation, 2010, 122(9): 920-927. [15] Baroja-Mazo A, Martín-Sánchez F, Gomez A I, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response [J]. Nat Immunol, 2014,15(8):738-748. [16] Cao K, Tang G, Hu D, et al. Molecular basis of ATP-sensitive K+ channels in rat vascular smooth muscles[J]. Biochem Biophys Res Commun, 2002, 296(2):463-469. [17] Hu H L, Zhang Z X, Chen C S, et al. Effects of mitochondrial potassium channel and membrane potential on hypoxic human pulmonary artery smooth muscle cells[J]. Am J Respir Cell Mol Biol, 2010, 42(6):661-666. [18] Dong L, Li Y, Hu H, et al. Potential therapeutic targets for hypoxia-induced pulmonary artery hypertension[J]. J Transl Med, 2014, 12:39. [19] Koh G C, Maude R R, Schreiber M F, et al. Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis[J]. Clin Infect Dis, 2011, 52(6):717-725. [20] Pétrilli V, Papin S, Dostert C, et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration[J]. Cell Death Differ, 2007, 14(9):1583-1589. )[ |